author-photo

Michel Fabbro

ICM Partners

220

Papers

4916

Citations

Citation Trend

Filter By

Papers (162) Sort By

Journal Conference Others

801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Lumbosacral Plexus Neurolymphomatosis: A Typical 18FDG PET/CT Pattern to Recognize.

2021 Clinical Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (0)
733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer—A CLIPP program INCA in collaboration with GINECO group.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
817TiP GYNET study - Safety and efficacy of anti-netrin 1 (NP137) in combination with chemotherapy and/or pembrolizumab in patients (pts) with pretreated locally advanced/metastatic endometrial carcinoma or cervix carcinoma: An adaptive multi-arms randomized phase I/II trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)